drugset
Drugs / cH5/1N1 IIV
last change Aug 2019 re-read 3 minutes ago

cH5/1N1 IIV

Vaccine

Developed for
influenza
Investigated by
Children's Hospital Medical Center, Cincinnati · Duke University · GlaxoSmithKline · Icahn School of Medicine at Mount Sinai · PATH · The Emmes Company, LLC

Trials 1

today NCT03300050 · Ph 1
2018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1 NCT03300050 Oct 2017 → Apr 2018 influenza PATH Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as cH5/1N1 IIV ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300050 ↗
Modality Vaccine “Chimeric H5 head with H1 stalk plus N1 (cH5/1N1) split virion inactivated influenza virus vaccine (IIV)” NCT03300050 ↗
Route Intramuscular “Administered intramuscularly at a dose of 15 μg of hemagglutinin” NCT03300050 ↗